Twist Bioscience Corporation (NasdaqGS: TWST)
Health Care · Biotechnology · US
$150.06
-0.90% today · +452.8% 1Y
Twist Bioscience Corporation (NasdaqGS: TWST) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.50B and employs 979 people.
Over the last twelve months the share price has gained 452.8%, trading between 23.30 and 142.84.
Tweenvest scores Twist Bioscience Corporation across four factors: quality 45/100, value 58/100, growth 100/100. Its strongest factor is growth.
TWST price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.50B
- Revenue (TTM)
- $431.80M
- P/E
- —
- EPS
- -2.23
- Dividend yield
- —
- Beta (5Y)
- 2.16
- 52-week high
- $142.84
- 52-week low
- $23.30
- Avg volume (3M)
- —
- Shares outstanding
- 62.71M
- Employees
- 979
- Next earnings
- —
About Twist Bioscience Corporation
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
- ISIN
- US90184D1000
- Founded
- 2013
- Listed since
- Oct 31, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.